Turn Therapeutics Inc.

As of June 30, 2026, Turn Therapeutics Inc. carries a market capitalization of 217.45M, placing it among publicly traded companies globally. Its enterprise value stands at 213.29M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Turn Therapeutics Inc.'s next confirmed earnings release is scheduled for November 12, 2026.

As of June 30, 2026, Turn Therapeutics Inc. has 29.79M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Turn Therapeutics Inc. maintains a current ratio of 1.19, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 891.13, indicating elevated leverage, while an interest coverage ratio of -18.36 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Turn Therapeutics Inc. posted a negative return on equity (ROE) of -686.27, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -79.33, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 2.00, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Turn Therapeutics Inc.'s stock has gained approximately 143.54% over the past 52 weeks. The 50-day moving average sits at 11.63, while the 200-day moving average is 6.82.

Over the twelve months ended June 30, 2026, Turn Therapeutics Inc. generated - - in revenue and converted that into -8.45M in net income, yielding earnings per share of -0.29. EBITDA reached -4.43M, while operating income came in at -6.98M.

As of June 30, 2026, Turn Therapeutics Inc. holds 10.29M in cash and equivalents against 6.12M in total debt, resulting in a net debt position of -4.23M. Total book value stands at 686,888.00, with working capital of 1.66M providing operational flexibility.

Turn Therapeutics Inc. produced -4.32M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -139,260.00 in capital expenditures, free cash flow totaled -4.46M - equivalent to -0.15 per share.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -2.07: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -5.32, meaning Turn Therapeutics Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Turn Therapeutics Inc. has an Altman Z-Score of 4.16, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.